Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: January 2012
-
By Kevin E. Noonan — The Leahy-Smith America Invents Act ("AIA") changes U.S. patent law in many ways, notably by converting our patent system to a "first inventor to file" system. However, the language of the new statute is not always "pelucidly clear" in achieving this change; one of the areas of murkiness involves the…
-
By Donald Zuhn — Last November, officials from the U.S. Patent and Trademark Office indicated that ten notices of proposed rulemaking to implement various provisions of the Leahy-Smith America Invents Act were being drafted and vetted by the Office, and that the notices would be published in January 2012. With January drawing to a close,…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cephalon Inc. v. Mylan Pharmaceuticals Inc. et al.1:12-cv-00073; filed January 24, 2012 in the District Court of Delaware • Plaintiff: Cephalon Inc.• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc. Cephalon Inc. v. Sandoz Inc.1:12-cv-00074; filed January…
-
January 31, 2012 – Obviousness Standard for Patents: Approaches to Withstand USPTO Obviousness Rejections and Attacks on Patent Validity (Strafford) – 1:00 – 2:30 pm (EST) January 31 – February 1, 2012 – Patent Reform for Life Sciences Companies*** (American Conference Institute) – New York, NY January 31 – February 1, 2012 – Pharma &…
-
By Donald Zuhn — USPTO Schedules Hearings and Seeks Comments on Genetic Diagnostic Testing In a press release and corresponding notice in Wednesday's Federal Register (77 Fed. Reg. 3748), the U.S. Patent and Trademark Office announced that it would begin gathering information on independent second opinion genetic diagnostic testing where patents and exclusive licenses exist…
-
By Andrew Williams — In a sequel of sorts to the hugely popular Streck, Inc. v. Research & Diagnostic Systems, Inc. (Fed. Cir. 2011), the Federal Circuit released Streck II (Streck, Inc. v. Research & Diagnostic Systems, Inc. (Fed. Cir. 2012)) earlier this month. Not to be upstaged by the original, this ambitious follow-up leaves…
-
By Kevin E. Noonan — One of the longest patent law sagas has apparently reached an end. As announced by The Medicines Company (MDCO) today, the drug developer has reached a settlement of litigation with APP Pharmaceuticals over Angiomax® (bivalirudin). Most important for MDCO, the settlement dismisses APP's appeal of the denial of its motion…
-
By Donald Zuhn — Last week, the Office of the General Counsel for the U.S. Patent and Trademark Office issued a memorandum in response to several inquiries the Office has received concerning copyright infringement and the use of non-patent literature (NPL) in the examination process. The memo, which was sent by USPTO General Counsel Bernard Knight,…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Alnylam Pharmaceuticals, Inc. et al. V. Tekmira Pharmaceuticals Corp.1:12-cv-10087; filed January 17, 2012 in the District Court of Massachusetts • Plaintiffs: Alnylam Pharmaceuticals, Inc.; Isis Pharmaceuticals Inc.• Defendant: Tekmira Pharmaceuticals Corp. Infringement of U.S. Patent…
-
January 25-26, 2012 – Biosimilars Forum 2012 (C5) – London, UK January 26, 2012 – Life Under AIA: Anticipating and Surviving Post Grant Challenges (Technology Transfer Tactics) – 1:00 – 2:00 pm (Eastern) January 31, 2012 – Obviousness Standard for Patents: Approaches to Withstand USPTO Obviousness Rejections and Attacks on Patent Validity (Strafford) – 1:00…
Patent Docs 